Parkinson's Disease is a forthcoming study from Decision Resources, Inc., that assesses the commercial opportunities for new drugs to treat this disease over a 2000-2010 forecast period.
Continued research into the neurochemical pathways involved in the degenerative process that occurs in the brains of Parkinson's disease (PD) patients has provided new targets for drug development. Pharmaceutical companies are now targeting both dopaminergic and nondopaminergic systems for the treatment of PD symptoms. New therapies will include novel dopamine agonists, compounds targeting nondopaminergic systems (e.g., glutamate antagonists), and neurotrophic factor therapies that may offer neuroprotection and/or neurorestoration. Emerging therapies for PD will most likely be used to delay the need for levodopa or as adjuncts to levodopa therapy, but none are expected to replace it.
The recent trend toward levodopa-sparing strategies as a way of delaying levodopa-induced motor response complications (MRCs) will result in the increased use of dopamine agonists. We expect two newer, non-ergot-derived dopamine agonists, ropinirole (GlaxoSmithKline's Requip) and pramipexole (Pharmacia's Mirapex) to remain the top-sellers in the United States during our forecast period, with ropinirole seeing a boost in sales upon the introduction of a once-daily, controlled-release formulation by 2005. Pergolide (Eli Lilly's Celance/Permax) will remain one of the most popular dopamine agonists in Europe and Japan, despite experiencing a modest decline in favor of newer agents. Two novel dopamine agonists, Schwarz Pharma's transdermal rotigotine and Pharmacia's PNU-95666, are expected to enter the market by 2005. These drugs will face considerable competition from several well-established drugs and so will most likely target niche populations (e.g., patients who prefer transdermal delivery or those with comorbid anxiety).
A fixed combination of levodopa-carbidopa plus the catechol-O- methyltransferase (COMT) inhibitor entacapone (Novartis's Comtan) as well as Lundbeck's new MAO-B inhibitor rasagiline and the novel glutamate antagonists riluzole (Aventis) and remacemide (AstraZeneca) are also expected to enter the market by 2005. These drugs will be used primarily as adjuncts to levodopa.
Parkinson's Disease offers invaluable market intelligence for pharmaceutical companies competing in this market, and is a part of Cognos, one of six Pharmacor services available from Decision Resources that evaluate the commercial potential of drugs in research and development.
Decision Resources, Inc., is a world leader in research publications and advisory services designed to help clients shape strategy, allocate resources, and master their chosen markets. Founded as a subsidiary of Arthur D. Little, Inc., the company has provided strategic information services for 30 years, assessing international pharmaceutical and health care industry trends. Visit Decision Resources at http://www.dresources.com/.
Contact Frank Sama, 781.296.2553 (tel), 781.296.2550 (fax), or email@example.com. In Europe, contact Francoise Bidart, +32.2.351.4082 (tel), +32.2.351.2347 (fax), or firstname.lastname@example.org. In Japan, contact Makiko Yoshimoto, +81.3.5401.2615 (tel), +81.3.5401.2617 (fax), or email@example.com.
AP Archive: http://photoarchive.ap.org/
PRN Photo Desk, 888-776-6555 or 212-782-2840
SOURCE: Decision Resources, Inc.
Contact: Frank Sama of Decision Resources, Inc., 781-296-2553,